Amgen sues Sandoz over Neulasta biosimilar

In a lawsuit, Amgen Inc. (NASDAQ:AMGN) alleged that the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) infringed two patents protecting Neulasta pegfilgrastim. FDA accepted Sandoz's BLA in November 2015 for LA-EP2006, a proposed Neulasta biosimilar (see BioCentury Extra, Nov. 18, 2015).

Amgen is seeking a jury trial and judgments that Sandoz infringed on U.S. Patents Nos. 8,940,878 and 5,824,784, as well as an injunction preventing manufacture or sale of the biosimilar before the '878 patent expires in 2031. Amgen filed the suit May 12 in the Northern District of California. ...